Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL BIOSIMILARS MARKET, BY PRODUCT
6.1. Overview
6.2. Recombinant Non-Glycosylated Proteins
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.1. Human Growth Hormone (RHGH)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2. Granulocyte Colony-Stimulating Factor (Filgrastim)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.3. Insulin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.4. Interferons
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Recombinant Glycosylated Proteins
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.1. Erythropoietin (EPO)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.2. Monoclonal Antibodies (MABS)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.3. Follitropin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Recombinant Peptides
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4.1. Glucagon
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4.2. Calcitonin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS
7.1. Overview
7.2. Oncology
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Chronic Diseases
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Autoimmune Diseases
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Blood Disorders
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.6. Growth Hormone Deficiency
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.7. Infectious Diseases
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.8. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL BIOSIMILARS MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Research Institutes
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL BIOSIMILARS MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Biosimilars Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Biosimilars Market
10.7. Key developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2020
10.8.2. Major Players R&D Expenditure 2020
10.9. Major Players Capital Market Ratio
11. COMPANY PROFILES
11.1. Pfizer
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Sandoz International
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Teva Pharmaceuticals
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Amgen, Inc.
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Biocon
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Dr. Reddy’s Laboratories
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Celltrion
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Samsung Biologics
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Eli Lily & Company
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Hospira Inc.
11.10.1. Company Overview
11.10.2. Product Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Actavis, Inc.
11.12. Cipla Ltd
11.13. Stada Arzneimittel Ag
11.14. Mylan, Inc.
11.15. Others
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL BIOSIMILARS MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL BIOSIMILARS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL BIOSIMILARS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 10 US: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 11 US: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 12 US: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 13 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 14 CANADA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 15 CANADA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 16 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 17 LATIN AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 18 LATIN AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 19 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 20 EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 21 EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 22 WESTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 23 WESTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 24 WESTERN EUROPE: BIOSIMILARS MARKET, BY END USERS E, 2020-2027 (USD MILLION)
TABLE 25 EASTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 26 EASTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 27 EASTERN EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BIOSIMILARS MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BIOSIMILARS MARKET
FIGURE 4 GLOBAL BIOSIMILARS MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 5 GLOBAL BIOSIMILARS MARKET SHARE, BY APPLICATIONS, 2020 (%)
FIGURE 6 GLOBAL BIOSIMILARS MARKET SHARE, BY END USERS, 2020 (%)
FIGURE 7 GLOBAL BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 AMERICAS: BIOSIMILARS MARKET SHAR,E BY REGION, 2020 (%)
FIGURE 9 NORTH AMERICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 EUROPE: BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 WESTERN EUROPE: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 ASIA-PACIFIC: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 14 GLOBAL BIOSIMILARS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 15 PFIZER: KEY FINANCIALS
FIGURE 16 PFIZER: SEGMENTAL REVENUE
FIGURE 17 PFIZER: REGIONAL REVENUE
FIGURE 18 SANDOZ INTERNATIONAL: KEY FINANCIALS
FIGURE 19 SANDOZ INTERNATIONAL: SEGMENTAL REVENUE
FIGURE 20 SANDOZ INTERNATIONAL: REGIONAL REVENUE
FIGURE 21 AMGEN, INC.: KEY FINANCIALS
FIGURE 22 AMGEN, INC.: SEGMENTAL REVENUE
FIGURE 23 AMGEN, INC.: REGIONAL REVENUE
FIGURE 24 TEVA PHARMACEUTICALS: KEY FINANCIALS
FIGURE 25 TEVA PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 26 TEVA PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 27 BIOCON: KEY FINANCIALS
FIGURE 28 BIOCON: SEGMENTAL REVENUE
FIGURE 29 BIOCON: REGIONAL REVENUE
FIGURE 30 DR. REDDY’S LABORATORIES: KEY FINANCIALS
FIGURE 31 DR. REDDY’S LABORATORIES: SEGMENTAL REVENUE
FIGURE 32 DR. REDDY’S LABORATORIES: REGIONAL REVENUE
FIGURE 33 CELLTRION: KEY FINANCIALS
FIGURE 34 CELLTRION: SEGMENTAL REVENUE
FIGURE 35 CELLTRION: REGIONAL REVENUE
FIGURE 36 SAMSUNG BIOLOGICS: KEY FINANCIALS
FIGURE 37 SAMSUNG BIOLOGICS: SEGMENTAL REVENUE
FIGURE 38 SAMSUNG BIOLOGICS: REGIONAL REVENUE
FIGURE 39 ELI LILY & COMPANY: KEY FINANCIALS
FIGURE 40 ELI LILY & COMPANY: SEGMENTAL REVENUE
FIGURE 41 ELI LILY & COMPANY: REGIONAL REVENUE
FIGURE 42 HOSPIRA INC.: KEY FINANCIALS
FIGURE 43 HOSPIRA INC.: SEGMENTAL REVENUE
FIGURE 44 HOSPIRA INC.: REGIONAL REVENUE
FIGURE 45 ACTAVIS, INC.: KEY FINANCIALS
FIGURE 46 ACTAVIS, INC.: SEGMENTAL REVENUE
FIGURE 47 ACTAVIS, INC.: REGIONAL REVENUE
FIGURE 48 CIPLA LTD.: KEY FINANCIALS
FIGURE 49 CIPLA LTD.: SEGMENTAL REVENUE
FIGURE 50 CIPLA LTD.: REGIONAL REVENUE
FIGURE 51 STADA ARZNEIMITTEL AG: KEY FINANCIALS
FIGURE 52 STADA ARZNEIMITTEL AG: SEGMENTAL REVENUE
FIGURE 53 STADA ARZNEIMITTEL AG: REGIONAL REVENUE
FIGURE 54 MYLAN, INC.: KEY FINANCIALS
FIGURE 55 MYLAN, INC.: SEGMENTAL REVENUE
FIGURE 56 MYLAN, INC.: REGIONAL REVENUE
